Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Hebei Medical University

Status and phase

Unknown

Phase 3

Phase 2

Conditions

Gastric Cancer

Treatments

Drug: Apatinib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02509806

Ahead-G309

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive Gastric Cancer.

Full description

Eligible patients will receive apatinib treatment(500mg qd p.o. q28d) until until disease progression or intolerable toxicity or patients withdrawal of consent after 4 cycles of DC first-line chemotherapy or only DC first-line chemotherapy.

Enrollment

48 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age: 18 to75 years old;
Histologically proven progressive gastric cancer. All pts were received D2 gastrectomy and recurrence / metastasis occured;
Complete 4 cycles DC first-line chemotherapy and no and no disease progression occurred. DC: Docetaxel 60-85mg/m2 iv d1, Cisplatin 60-75mg/m2 iv d1, q21d;
ECOG PS of 0-1;
Major organ function has to meet the following criteria:

ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; Bilirubin <1.5 times the upper limit of normal (ULN); ALT and AST <2.5 × ULN; liver metastases, if any, the ALT and AST<5 × ULN;
An expected survival of ≥ 3 months;
Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.
Patient has to voluntarily join the study and sign the Informed Consent Form for the study;

Exclusion criteria

Confirmed that apatinib and/or its accessories allergy;
Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than ClassI; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac dysfunction;
Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;
Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
Associated with CNS (central nervous system) metastases;
Pregnant or lactating women;
Pts with other malignant tumor within 5 years(except cured skin basal cell carcinoma and cervical carcinoma);
With psychotropic drug abuse history and can't get rid of or mental disorder patients;
Participated in other clinical trials within 4 weeks.
Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);
Any other condition that might place the patient at undue risk or preclude a patient from completing the study;
Other conditions regimented at investigators' discretion.